SECONDARY PREVENTION OF SMALL SUBCORTICAL STROKES (SPS3)

小皮质下中风的二级预防 (SPS3)

• 批准号: 7376027
• 负责人: STANLEY COHEN
• 金额: $ 1.75万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376027
• 关键词: SECONDARY; PREVENTION; SMALL; SUBCORTICAL; STROKES

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to gather information about a new treatment that might help prevent another stroke from happening in people who have suffered a "lacunar stroke." Aspirin is the medicine most widely used and is the standard therapy for this type of stroke. Clopidogrel is another medicine doctors use to prevent stroke. Both of these medicines have an effect on blood clotting and are now widely prescribed by doctors for stroke prevention. However, using them together has not been tested. We want to learn if using them together is more effective than aspirin alone. We also want to find out if lowering a patient's blood pressure below the usual limits will also help prevent stroke and maintain thinking ability.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项研究的目的是收集有关一种新的治疗方法的信息，这种治疗方法可能有助于防止“腔隙性中风”患者再次中风。阿司匹林是使用最广泛的药物，也是治疗这类中风的标准药物。氯吡格雷是医生用来预防中风的另一种药物。这两种药物都对血液凝固有影响，现在被医生广泛用于预防中风。然而，将它们一起使用还没有经过测试。我们想知道两者一起使用是否比单独使用阿司匹林更有效。我们还想知道，将患者的血压降至正常范围以下是否也有助于预防中风和保持思维能力。